Riera-Guardia N, Rothenbacher D
Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany.
Diabetes Obes Metab. 2008 May;10(5):367-75. doi: 10.1111/j.1463-1326.2007.00755.x. Epub 2007 Jul 21.
Adiponectin is a hormone mainly produced by white adipose tissue. Decreased levels of adiponectin are linked with visceral obesity, insulin resistance states, and cardiovascular diseases. Recently, several studies have pointed out an increase in adiponectin serum levels in subjects undergoing treatment with thiazolidinediones (TZD). The aim of this study is to systematically review the current state of evidence of the effect of TZD on adiponectin serum level with special attention to avoid publication bias.
An extensive literature search was performed. Meta Analysis Version 2.0 computer program was used to calculate statistical differences in means and 95% confidence interval (CI). Publication bias was assessed using different statistical approaches.
In the meta-analysis including 19 studies the overall standardized mean difference was 0.94 (95% CI, 0.81-1.06) which means that subjects treated with TZDs on average had means of adiponectin concentration that were about 1 standard deviation higher than the comparison groups even after controlling for possible biases.
The results obtained agree with a moderate increase of serum adiponectin. The results clearly reveal an increase of endogenous serum adiponectin levels by intake of TZDs and may point to a potential new option to manage obesity-related diseases.
脂联素是一种主要由白色脂肪组织产生的激素。脂联素水平降低与内脏肥胖、胰岛素抵抗状态及心血管疾病相关。最近，多项研究指出接受噻唑烷二酮类药物（TZD）治疗的受试者血清脂联素水平升高。本研究旨在系统评价TZD对血清脂联素水平影响的现有证据状况，特别关注避免发表偏倚。
进行了广泛的文献检索。使用Meta分析2.0计算机程序计算均值的统计学差异及95%置信区间（CI）。采用不同的统计学方法评估发表偏倚。
在纳入19项研究的荟萃分析中，总体标准化均值差为0.94（95%CI，0.81 - 1.06），这意味着即使在控制了可能的偏倚后，接受TZD治疗的受试者脂联素浓度均值平均比对照组高约1个标准差。
获得的结果与血清脂联素适度升高一致。结果清楚地表明，摄入TZD可使内源性血清脂联素水平升高，这可能为管理肥胖相关疾病指出一个潜在的新选择。
